Table 1.

Corneal inflammatory cell count at TP.0 and on outcome in the following 6 months.

	Cell count at TP.0 median (range)		Cell count at TP.0 median (range)		Cell count at TP.0 median (range)
Clinical stable at TP.0 (n = 74)	14 (0–349)	INCAT-ODSS stable at TP.0 (n = 119)	18 (0–365)	No therapy escalation at TP.0 (n = 97)	20 (1–365)
Clinical active at TP.0 (n = 61)	54 (0–365)	INCAT-ODSS instable at TP.0 (n = 22)	54 (1–135)	Therapy escalation at TP.0 (n = 40)	28 (0–194)
p-value	0.0009	p-value	0.018	p-value	n.s.
Clinical stable at TP.3 (n = 80)	16 (1–365)	INCAT-ODSS stable at TP.3 (n = 93)	19 (0–365)	No therapy escalation at TP.3 (n = 78)	16 (0–365)
Clinical active at TP.3(n = 20)	54 (0–181)	INCAT-ODSS instable at TP.3 (n = 9)	64 (16–158)	Therapy escalation at TP.3 (n = 22)	31 (3–181)
p-value	0.016	p-value	0.016	p-value	n.s.
Clinical stable at TP.6 (n = 79)	19 (3–349)	INCAT-ODSS stable at TP.6 (n = 79)	20 (3–349)	No therapy escalation at TP.6 (n = 80)	23 (3–349)
Clinical active at TP.6 (n = 14)	32 (0–163)	INCAT-ODSS instable at TP.6 (n = 14)	32 (0–194)	Therapy escalation at TP.6 (n = 12)	32 (3–158)
p-value	n.s.	p-value	n.s.	p-value	n.s.

p-values were corrected by the Holm–Bonferroni method, groups were formed according to the outcome parameter.

The different n-values at TP.0, TP.3 and TP.6 are a result of “loss to follow-up”.